RenalytixAI is a developer of artificial intelligence (“AI”) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
The Company’s technology platform will draw from distinct sources of patient data, including systems containing extensive electronic health records, predictive blood-based biomarkers and other genomic information for analysis by high-performance, learning computer algorithms (machine learning). The Company intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time.
In May 2018, the Company secured a cornerstone collaboration with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), the medical school of the Mount Sinai Health System, for product development and intended commercialisation by the Company beginning in 2019. As part of the collaboration, Mount Sinai became a shareholder in the Company and has made a further equity investment in the Fundraising.
The Company believes that its current business model of collaborating with major medical centers whose patients are most likely to benefit from its products will provide an effective opportunity to commercialise its products. The Company intends to enter into further collaborations beginning in 2019.